Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.

D'Arena, G., Sgambato, A., Volpe, S., Coppola, G., Amodeo, R., Tirino, V., D'Auria, F., Statuto, T., Valvano, L., Pietrantuono, G., Deaglio, S., Efremov, D., Laurenti, L., Aiello, A., Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?, <<HEMATOLOGICAL ONCOLOGY>>, 2022; 40 (5): 835-842. [doi:10.1002/hon.3037] [https://hdl.handle.net/10807/235631]

Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Sgambato, Alessandro;Efremov, Dimitar;Laurenti, Luca;Aiello, Antimo
2022

Abstract

Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.
2022
Inglese
D'Arena, G., Sgambato, A., Volpe, S., Coppola, G., Amodeo, R., Tirino, V., D'Auria, F., Statuto, T., Valvano, L., Pietrantuono, G., Deaglio, S., Efremov, D., Laurenti, L., Aiello, A., Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?, <<HEMATOLOGICAL ONCOLOGY>>, 2022; 40 (5): 835-842. [doi:10.1002/hon.3037] [https://hdl.handle.net/10807/235631]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/235631
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact